title: Treatment: symptomatic treatment of hypoglycaemia.
authors.affiliation: Service d'endocrinologie-diabétologie et maladies métaboliques, hôpital Haut-Lévêque, groupe hospitalier Sud, CHU de Bordeaux, 33604 Pessac cedex, France. antoine.tabarin@chu-bordeaux.fr
authors.forename: Antoine
authors.initials: A
authors.lastname: Tabarin
authors.forename: Bernard
authors.initials: B
authors.lastname: Goichot
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects / Q000502:physiology; D003981:Diazoxide / Q000627:therapeutic use; D000068338:Everolimus; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology / Q000628:therapy*; D007340:Insulinoma / Q000150:complications / Q000188:drug therapy; D015282:Octreotide / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D001786:Blood Glucose; D047428:Protein Kinase Inhibitors; D013004:Somatostatin; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D003981:Diazoxide; D015282:Octreotide; D020123:Sirolimus